Back to search
Menkes Syndrome
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Menkes Syndrome trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Menkes Syndrome trials you may qualify forThis clinical trial will evaluate the safety, tolerability, dosing, and efficacy of Northera (Droxidopa) in children with Menkes disease aged 7 to 17 years who…
This is a single-arm, open, dose-increasing and dose-expanding phase I clinical trial to investigate the safety, tolerability and cytodynamic characteristics of…
This is a single-arm, open-label, dose-escalation phase I clinical study to explore the safety, tolerability, and cytokinetic characteristics of MC-1-50 cell fo…
The purpose of this study is to evaluate whether Northera (Droxidopa) is safe and effective in young adults with Menkes disease who survived the most severe com…
This expanded access protocol provides subcutaneous copper histidinate for Menkes disease patients under 6 years of age.
This study will collect long term follow-up data regarding overall survival and neurological parameters from patients previously identified and/or enrolled in P…